Impact of Protein Nanoparticle Shape on the Immunogenicity of Antimicrobial Glycoconjugate Vaccines
-
Published:2024-03-27
Issue:7
Volume:25
Page:3736
-
ISSN:1422-0067
-
Container-title:International Journal of Molecular Sciences
-
language:en
-
Short-container-title:IJMS
Author:
Dolce Marta12ORCID, Proietti Daniela2, Principato Silvia2, Giusti Fabiola2, Adamo Giusy Manuela2, Favaron Sara23ORCID, Ferri Elia2, Margarit Immaculada2, Romano Maria Rosaria2, Scarselli Maria2, Carboni Filippo2ORCID
Affiliation:
1. Department of Biotechnology, Chemistry and Pharmacy, University of Siena, 53100 Siena, Italy 2. GSK, 53100 Siena, Italy 3. Department of Chemistry, Materials and Chemical Engineering, Politecnico di Milano, 20133 Milano, Italy
Abstract
Protein self-assembling nanoparticles (NPs) can be used as carriers for antigen delivery to increase vaccine immunogenicity. NPs mimic the majority of invading pathogens, inducing a robust adaptive immune response and long-lasting protective immunity. In this context, we investigated the potential of NPs of different sizes and shapes—ring-, rod-like, and spherical particles—as carriers for bacterial oligosaccharides by evaluating in murine models the role of these parameters on the immune response. Oligosaccharides from Neisseria meningitidis type W capsular polysaccharide were conjugated to ring-shape or nanotubes of engineered Pseudomonas aeruginosa Hemolysin-corregulated protein 1 (Hcp1cc) and to spherical Helicobacter pylori ferritin. Glycoconjugated NPs were characterized using advanced technologies such as High-Performance Liquid Chromatography (HPLC), Asymmetric Flow-Field Flow fractionation (AF4), and Transmission electron microscopy (TEM) to verify their correct assembly, dimensions, and glycosylation degrees. Our results showed that spherical ferritin was able to induce the highest immune response in mice against the saccharide antigen compared to the other glycoconjugate NPs, with increased bactericidal activity compared to benchmark MenW-CRM197. We conclude that shape is a key attribute over size to be considered for glycoconjugate vaccine development.
Reference87 articles.
1. Varki, A., Cummings, R.D., Esko, J.D., Stanley, P., Hart, G.W., Aebi, M., Mohnen, D., Kinoshita, T., Packer, N.H., and Prestegard, J.H. (2015). Essentials of Glycobiology, Cold Spring Harbor Laboratory Press. [3rd ed.]. 2. Biological roles of glycans;Varki;Glycobiology,2017 3. Hulbert, S.W., Desai, P., Jewett, M.C., DeLisa, M.P., and Williams, A.J. (2023). Glycovaccinology: The design and engineering of carbohydrate-based vaccine components. Biotechnol. Adv., 68. 4. Recent advances on smart glycoconjugate vaccines in infections and cancer;Anderluh;FEBS J.,2022 5. On the mechanisms of conjugate vaccines;Rappuoli;Proc. Natl. Acad. Sci. USA,2019
|
|